PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-1.08
Negative D/E while Biotechnology median is 0.00. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
-6.56
Net cash position versus Biotechnology median net debt of 0.89. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-32.85
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.75
Current ratio 50-75% of Biotechnology median of 3.48. Martin Whitman would look for hidden assets or working capital optimization.
No Data
No Data available this quarter, please select a different quarter.